Project Grant R21OH012630

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $166,000 to the University of Southern California to examine how implicit attitudes towards physical activity can mediate the effects of different interventions on physical activity behavior among adults at elevated cancer risk due to inactivity and overweight/obesity. The key products or services being delivered under this grant include: 1) Assessing implicit attitudes...

The National Cancer Institute (NCI) awarded a $414,446 Project Grant to Colorado State University (CSU) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct a 12-week group-based videoconference intervention aimed at increasing moderate to vigorous physical activity (MVPA) among cancer survivors. The goal is to examine the efficacy of this virtual exercise intervention in improving physical function, quality of life, and other health outcomes for this population....

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $671,757 to Virginia Commonwealth University to conduct the "Supportive Tailored Exercise Program for Survivors of Breast Cancer (STEPS-BC)" study. The objective is to test whether a tailored home-based exercise intervention, delivered in parallel with adjuvant chemotherapy, can preserve exercise capacity, left ventricular function, and health-related quality...

Federal Grant Award Summary The National Cancer Institute awarded the University of Miami a $2.75 million Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) on September 12, 2025, for a study examining the effects of remotely-delivered cognitive behavioral stress management on cancer-accelerated aging in older breast cancer survivors. The project, which runs through August 31, 2029, will enroll 192 breast cancer survivors aged 50 and older who have completed...

Summary Mayo Clinic was awarded $823,878 on September 4, 2025, under the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) to conduct a Phase II randomized, double-blind, parallel-group clinical trial evaluating vagal nerve stimulation (VNS) as a novel treatment for tobacco use disorder (TUD) in conjunction with nicotine replacement therapy (NRT). The research project, scheduled for completion by August 31, 2027, will assess the efficacy of combining active VNS with NRT...

Cooperative Agreement Summary The National Institute on Drug Abuse (NIDA) awarded Fred Hutchinson Cancer Center a $2.68 million Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate ACTIFY!, a mobile health application designed to improve smoking cessation outcomes by integrating behavioral activation therapy with standard cessation support. The award, effective September 1, 2025, through July 31, 2030, supports a fully-powered...

This $2.9 million Defense Health Agency project grant funds research on suicide prevention among military personnel and veterans. The grant supports a multi-site randomized clinical trial through September 2026 to evaluate the efficacy of Written Exposure Therapy for Suicide Prevention compared to treatment as usual. Researchers at Boston University and partner institutions University of Colorado Denver and University of Texas Health Science Center San Antonio aim to reduce suicidal thoughts and...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $416,818 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Massachusetts General Hospital (MGH) for a two-year research project running from August 1, 2025 through July 31, 2027. The project focuses on improving chimeric antigen receptor (CAR)-T cell immunotherapy effectiveness in metastatic breast cancer by investigating how physical activity can reprogram the tumor microenvironment. The...

Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $817,829 Project Grant on September 12, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized controlled trial testing the efficacy of SMART3RP-Lymphoma, a virtual, resilience-based group intervention designed to improve quality of life in lymphoma survivors during early post-treatment survivorship (0-2 years after curative-intent treatment). The study will enroll 254...

This $189,163 federal Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to investigate the impact of dietary patterns and physical activity on survival outcomes for patients with renal cell carcinoma (RCC). The research team at Brigham & Women's Hospital, with the University of California, San Francisco as a sub-grantee, will leverage data from three large, prospective cohorts to comprehensively evaluate pre-...